Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer [2] (multiple letters)

New England Journal of Medicine

Volumn 349, Issue 14, 2003, Pages 1385-1387

  Blot, Emmanuel ^a   Gutman, Fabrice ^a   Thannberger, Alexia ^a   Hull, James H K ^b   Hull, Peter J ^c   Kaufman, Jeffrey L ^d   Nader, François ^e   Lee, Agnes Y Y ^f   Levine, Mark N ^f   Gent, Michael ^f   Bick, Rodger L ^g  

^a CENTRE HENRI BECQUEREL   (France)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Abbotsbury Road Primary Care Centre   (United Kingdom)

^d Vascular Svcs of Wstrn New England   (United States)

^e SANOFI   (France)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; COUMARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; ACENOCOUMAROL;

BLEEDING; CANCER PATIENT; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COST; DRUG SAFETY; HEALTH CARE COST; HUMAN; LETTER; META ANALYSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS PREVENTION; AGE; AGED; CHEMICALLY INDUCED DISORDER; NOTE; RISK; VEIN THROMBOSIS; ECONOMICS; SUBCUTANEOUS DRUG ADMINISTRATION; PATIENT SATISFACTION; EPIDEMIOLOGY; INTERNATIONAL NORMALIZED RATIO; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE;

AGE FACTORS; AGED; ANTICOAGULANTS; DALTEPARIN; ENOXAPARIN; HEMORRHAGE; HUMANS; META-ANALYSIS; RISK; VENOUS THROMBOSIS; COST-BENEFIT ANALYSIS; INJECTIONS, SUBCUTANEOUS; WARFARIN; PATIENT SATISFACTION; ACENOCOUMAROL; ADMINISTRATION, ORAL; BIAS (EPIDEMIOLOGY); INTERNATIONAL NORMALIZED RATIO; RECURRENCE; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 9144272603     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200310023491418     Document Type: Letter

References (0)